USPTO Patent for Alzheimer's Detection Kits

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 17th, 2026

Detected March 22nd, 2026

Summary

The USPTO has granted a patent (US12578344B2) to NEUROQUEST LTD. for compositions, kits, and methods for detecting preclinical Alzheimer's Disease. The patent covers binding agents for biomarkers such as CD163 and scavenger receptors, and methods for diagnosing AD and assessing therapeutic efficacy.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12578344B2 to NEUROQUEST LTD. This patent covers novel compositions, kits, and methods for the diagnosis and prognosis of Alzheimer's Disease (AD) in patients. The invention utilizes binding agents, such as monoclonal antibodies, that target specific biomarkers including CD163, CD91, CD59, MerTK, and other phagocytosis-related molecules. The patent also describes the use of panels of fluorophore-conjugated antibodies and methods for evaluating the efficacy of AD therapeutics.

While this is a patent grant and not a regulatory rule, it signifies a new intellectual property in the field of Alzheimer's diagnostics. Companies involved in developing diagnostic tools, therapeutic candidates for AD, or related research may need to be aware of this patent's claims to avoid potential infringement. The patent's claims focus on specific biomarkers and diagnostic methodologies, which could influence future research and development pathways in AD detection and treatment.

Source document (simplified)

← USPTO Patent Grants

Compositions, kits, and methods for detecting preclinical alzheimer's disease

Grant US12578344B2 Kind: B2 Mar 17, 2026

Assignee

NEUROQUEST LTD.

Inventors

Xin Huang, Yihan Li, James Doecke, Baijun Gu, Michal Eisenbach-Schwartz

Abstract

Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.